NCT04572776 2021-11-09
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Sorrento Therapeutics, Inc.
Phase 3 Withdrawn
Sorrento Therapeutics, Inc.
Fujian Cancer Hospital
Haukeland University Hospital
Fraser Health